NICE rejection
NICE rejects Enhertu for HER2-low breast cancer over cost concerns
Anika Sharma
The remarkable efficacy data that initially earned AstraZeneca and Daiichi Sankyo’s Enhertu a standing ovation at the ASCO meeting last ...
The remarkable efficacy data that initially earned AstraZeneca and Daiichi Sankyo’s Enhertu a standing ovation at the ASCO meeting last ...